InGeneron announces successful certification under the EU Medical Device Regulation (MDR) (EU) 2017/745.
This milestone reinforces our commitment to quality and patient safety in the EU.
#MDR#MedicalDevices#Biotechnology#InGeneron
This study completes a decade of scientific validation of our therapeutic approach through peer-reviewed data:
✅ Consistent cell characterization
✅ In Vivo Regeneration
✅ Human Biopsy Evidence
✅ Clinical Trial Data
Unlocking Your Body's Healing Potential: Discover how InGeneron's Transpose® RT platform utilizes your own regenerative cells for tissue repair.
Visit our website to learn more about our cell therapy. https://t.co/XmEi1iv4vY
InGeneron will be attending the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting in San Francisco from February 12 - 16, 2024. We look forward to connecting with existing partners and fostering new collaborations to drive the future of regenerative medicine.
InGeneron reports positive long-term results for its cell therapy in partial-thickness rotator cuff tears. The randomized controlled trial, published in Nature's Scientific Reports, met primary endpoints, and finds significant patient benefit 3.4 years post-treatment.
InGeneron announces encouraging results from @EmoryUniversity 480-Patient Knee Osteoarthritis Trial. Published in @NatureMedicine, the study describes InGeneron’s cell therapy as clinically effective and “confirms an exceptional safety profile”.
InGeneron is excited to attend The MedTech Conference from October 9-11, 2023 at the Anaheim Convention Center. We look forward to connecting with existing partners and fostering new collaborations to drive the future of regenerative medicine.
Happy Labor Day! Today, we celebrate the remarkable contributions of our dedicated team in the science and technology industry. At InGeneron, we are grateful for their hard work and unwavering commitment to innovation. #LaborDay2023#InGeneron#ScienceAndTechnology#Innovation
Exciting team growth at InGeneron! Welcoming Annette Zinn, J.D., Ph.D., as our new Director of Regulatory Affairs. With over 40 years of medical device regulatory experience, Annette's expertise will advance our mission to bring life-changing treatments to patients.
InGeneron's pipeline is developing advanced regenerative therapies for a wide range of diseases and injuries. Discover how our innovative technologies are changing the game at https://t.co/DRa8PYI298. #celltherapy#regenerativemedicine#innovation
InGeneron is committed to advancing the field of regenerative medicine through our innovative cell therapy products. Learn more about our technology and approach at https://t.co/4sCCiCUdcj #regenerativemedicine#stemcells#celltherapy